Please use this identifier to cite or link to this item: https://doi.org/10.2217/pgs.12.24
DC FieldValue
dc.titleCYP2C19 and PON1 polymorphisms regulating clopidogrel bioactivation in Chinese, Malay and Indian subjects
dc.contributor.authorChan, M.Y.
dc.contributor.authorTan, K.
dc.contributor.authorTan, H.-C.
dc.contributor.authorHuan, P.-T.
dc.contributor.authorLi, B.
dc.contributor.authorPhua, Q.-H.
dc.contributor.authorLee, H.-K.
dc.contributor.authorLee, C.-H.
dc.contributor.authorLow, A.
dc.contributor.authorBecker, R.C.
dc.contributor.authorOng, W.-C.
dc.contributor.authorRichards, M.A.
dc.contributor.authorSalim, A.
dc.contributor.authorTai, E.-S.
dc.contributor.authorKoay, E.
dc.date.accessioned2014-11-26T05:02:42Z
dc.date.available2014-11-26T05:02:42Z
dc.date.issued2012-04
dc.identifier.citationChan, M.Y., Tan, K., Tan, H.-C., Huan, P.-T., Li, B., Phua, Q.-H., Lee, H.-K., Lee, C.-H., Low, A., Becker, R.C., Ong, W.-C., Richards, M.A., Salim, A., Tai, E.-S., Koay, E. (2012-04). CYP2C19 and PON1 polymorphisms regulating clopidogrel bioactivation in Chinese, Malay and Indian subjects. Pharmacogenomics 13 (5) : 533-542. ScholarBank@NUS Repository. https://doi.org/10.2217/pgs.12.24
dc.identifier.issn14622416
dc.identifier.urihttp://scholarbank.nus.edu.sg/handle/10635/108902
dc.description.abstractAim, materials & methods: We investigated the functional significance of CYP2C19*2, *3, *17 and PON1 Q192R SNPs in 89 consecutive Asian patients on clopidogrel treatment and the prevalence of functionally significant polymorphisms among 300 Chinese, Malays and Asian Indians. Results: Both CYP2C19 loss-of-function alleles (*2 or *3) were associated with higher platelet reactivity while the CYP2C19 gain-of-function allele (*17) had lower platelet reactivity. For PON1, the median PRI was not significantly different between the QQ, QR and RR groups. The allele frequencies of CYP2C19*2, CYP2C19*3 and CYP2C19*17 were 0.280, 0.065 and 0.010 (rare) for Chinese, 0.310, 0.050 and 0.025 for Malays, and 0.375, 0.010 (rare) and 0.165 for Indians, respectively. Conclusion: Our data suggest that genotyping studies to investigate clopidogrel response should include CYP2C19*2 and *3 but not *17 polymorphisms in Chinese, and CYP2C19*2 and *17 polymorphisms but not *3 in Indians. All three polymorphisms should preferably be genotyped in Malays. Original submitted 16 December 2011; Revision submitted 16 February 201. © 2012 Future Medicine Ltd.
dc.description.urihttp://libproxy1.nus.edu.sg/login?url=http://dx.doi.org/10.2217/pgs.12.24
dc.sourceScopus
dc.subjectAsian
dc.subjectclopidogrel
dc.subjectCYP2C19
dc.subjectmetabolism
dc.subjectpharmacogenetics
dc.subjectPON1
dc.typeArticle
dc.contributor.departmentSAW SWEE HOCK SCHOOL OF PUBLIC HEALTH
dc.description.doi10.2217/pgs.12.24
dc.description.sourcetitlePharmacogenomics
dc.description.volume13
dc.description.issue5
dc.description.page533-542
dc.description.codenPARMF
dc.identifier.isiut000302331400012
Appears in Collections:Staff Publications

Show simple item record
Files in This Item:
There are no files associated with this item.

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.